Obexelimab Clinical Trial for Systemic Lupus Erythematosus (SLE)
Obexelimab Clinical Trial for Systemic Lupus Erythematosus (SLE)
Now Recruiting Participants
Lupus Canada is sharing information about a clinical trial currently recruiting individuals with Systemic Lupus Erythematosus (SLE) at Richmond Clinical Trials. This Phase 2 study aims to evaluate the safety and tolerability of Obexelimab, a monoclonal antibody designed to regulate B cell activity in lupus patients.
Key Details:
- Location: Richmond Clinical Trials
- Study Phase: Phase 2
- Treatment: Subcutaneous administration of Obexelimab
- Cost: No cost to participate; compensation may be available
- Eligibility: Patients must meet specific inclusion criteria (see below)
Eligibility Criteria:
Main Inclusion Criteria:
- Age: 18-70 years old
- Diagnosis: Confirmed SLE diagnosis for at least 24 weeks
- Active Lupus: Must meet disease activity thresholds based on BILAG-2004 and hSLEDAI
- Treatment: Currently on at least one of the following:
- Oral corticosteroid
- Antimalarial
- Immunosuppressant
- Autoantibodies: At least one of the following positive tests:
- Anti-nuclear antibody (ANA) ≥ 1:80
- Positive anti-dsDNA
- Positive anti-Sm
Main Exclusion Criteria:
- Recent thrombosis or embolism (within 6 months)
- Other autoimmune or inflammatory diseases (e.g., psoriasis, systemic sclerosis)
- Acute hepatitis B infection
- History of malignancy (within the past 5 years)
- Unstable medical conditions
- BMI <18 or >40.0 kg/m²
- History of alcohol or drug abuse (in the past 12 months)
For more information about this trial, please contact Richmond Clinical Trials.